These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 34915073)

  • 1. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
    Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW
    Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
    Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
    BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
    Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
    Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.
    Shah SA; Robertson C; Rudan I; Murray JL; McCowan C; Grange Z; Buelo A; Sullivan C; Simpson CR; Ritchie LD; Sheikh A
    J Glob Health; 2022; 12():05008. PubMed ID: 35356660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Hall VJ; Foulkes S; Saei A; Andrews N; Oguti B; Charlett A; Wellington E; Stowe J; Gillson N; Atti A; Islam J; Karagiannis I; Munro K; Khawam J; Chand MA; Brown CS; Ramsay M; Lopez-Bernal J; Hopkins S;
    Lancet; 2021 May; 397(10286):1725-1735. PubMed ID: 33901423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.
    Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    Lancet Microbe; 2022 Dec; 3(12):e944-e955. PubMed ID: 36375482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines.
    Vicini S; Bellini D; Iannarelli A; Rengo M; Pelle G; Ruggiero S; Fusco M; Ambrogi C; Carbone I
    AJR Am J Roentgenol; 2022 Nov; 219(5):752-761. PubMed ID: 35642761
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    Thompson MG; Burgess JL; Naleway AL; Tyner H; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes AL; Lutrick K; Groom HC; Dunnigan K; Odean MJ; Hegmann K; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Kuntz JL; Zunie T; Thiese MS; Ivacic L; Wesley MG; Mayo Lamberte J; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Poe BP; Lynch B; Zhou Y; Zhang J; Kelleher A; Li Y; Dickerson M; Hanson E; Guenther K; Tong S; Bateman A; Reisdorf E; Barnes J; Azziz-Baumgartner E; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
    N Engl J Med; 2021 Jul; 385(4):320-329. PubMed ID: 34192428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    Horne EMF; Hulme WJ; Keogh RH; Palmer TM; Williamson EJ; Parker EPK; Green A; Walker V; Walker AJ; Curtis H; Fisher L; MacKenna B; Croker R; Hopcroft L; Park RY; Massey J; Morley J; Mehrkar A; Bacon S; Evans D; Inglesby P; Morton CE; Hickman G; Davy S; Ward T; Dillingham I; Goldacre B; Hernán MA; Sterne JAC
    BMJ; 2022 Jul; 378():e071249. PubMed ID: 35858698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network.
    Bettinger JA; Irvine MA; Shulha HP; Valiquette L; Muller MP; Vanderkooi OG; Kellner JD; Top KA; Sadarangani M; McGeer A; Isenor JE; Marty K; Soe P; De Serres G;
    Clin Infect Dis; 2023 Mar; 76(6):1088-1102. PubMed ID: 36310514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.